Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
NCT ID: NCT01703468
Last Updated: 2018-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
59 participants
INTERVENTIONAL
2009-09-30
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
NCT00616863
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
NCT00618046
Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions
NCT00616681
Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5 mL Under Fasting Conditions
NCT00951600
Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed Condition
NCT00951847
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxcarbazepine then Trileptal
600 mg suspension
Oxcarbazepine
Trileptal then Oxcarbazepine
600 mg suspension
Oxcarbazepine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxcarbazepine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to oxcarbazepine or any comparable or similar product.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roxane Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cynthia Zamora, MD
Role: PRINCIPAL_INVESTIGATOR
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research)
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OXCA-S600-PVFD-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.